Using deep learning to identify bladder cancers with FGFR-activating mutations from histology images.

Journal: Cancer medicine
Published Date:

Abstract

BACKGROUND: In recent years, the fibroblast growth factor receptor (FGFR) pathway has been proven to be an important therapeutic target in bladder cancer. FGFR-targeted therapies are effective for patients with FGFR mutation, which can be discovered through genetic sequencing. However, genetic sequencing is not commonly performed at diagnosis, whereas a histologic assessment of the tumor is. We aim to computationally extract imaging biomarkers from existing tumor diagnostic slides in order to predict FGFR alterations in bladder cancer.

Authors

  • Constantine S Velmahos
    University of Massachusetts Medical School, Worcester, MA, USA.
  • Marcus Badgeley
    Icahn School of Medicine at Mount Sinai, New York, USA.
  • Ying-Chun Lo
    Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA.